What is Profusa, Inc. (PFSA) stock price today?

Profusa, Inc. (PFSA) is currently trading at $1.42, down 4.7% today.

What is PFSA P/E ratio?

Profusa, Inc.'s P/E ratio is -0.01. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is PFSA return on equity (ROE)?

Profusa, Inc.'s return on equity (ROE) is 148.25%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Profusa, Inc.'s market cap?

Profusa, Inc. has a market capitalization of $1.57M.

NASDAQ · Medical - Equipment & Services

Profusa, Inc. (PFSA) Stock

$1.42 -4.70% NASDAQ: PFSA Healthcare

Valuation

Metric	Value
Price	$1.42
Market Cap	$1.57M
P/E Ratio	-0.01
P/B Ratio	-0.01
P/S Ratio	0.00
EPS (TTM)	$-107.01
52-Week High	$3000.00
52-Week Low	$1.42
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	148.25%
ROA	-900.00%
ROCE	72.22%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.52
Current Ratio	0.18

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-12.0M	$-11.0M	$-6.0M	$-4.0M	$-13.0M
Net Profit	$-10.0M	$-20.0M	$-10.0M	$-9.0M	$-36.0M
EPS	$-31.99	$-62.74	$-76.65	$-357.13	$-107.01
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$11.0M	$1.0M	$2.0M	$3.0M	$4.0M
Total Liabilities	$95.0M	$101.0M	$112.0M	$122.0M	$30.0M
Cash	$1.0M	$0	$0	$0	$2.0M
Borrowings	$24.0M	$31.0M	$40.0M	$48.0M	$15.0M

Latest News

This Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Year Stocktwits · Jul 2, 2026 Profusa to Implement 1-for-25 Reverse Stock Split MT Newswires · Jul 2, 2026 Profusa Announces 1-for-25 Reverse Stock Split GlobeNewswire · Jul 2, 2026 BC-Most Active Stocks Associated Press · Jun 24, 2026 Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts GlobeNewswire · Jun 24, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-11.0M	$-8.0M	$-4.0M	$-2.0M	$-16.0M
Investing Cash Flow	$0	$0	$0	$0	$-2.0M
Financing Cash Flow	$0	$-1.0M	$-1.0M	$-1.0M	$10.0M
Net Cash Flow	$-2.0M	$-1.0M	$0	$0	$2.0M
Free Cash Flow	$-11.0M	$-8.0M	$-4.0M	$-2.0M	$-16.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.44
FCF Yield	-967.44%
Quick Ratio	0.18
Interest Coverage	-2.60
Return 1Y	-99.93%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held1.02%

Institutions Held0.58%

Institutions Float Held0.58%

Institutional Holder	Shares	Report Date
Citadel Advisors Llc	1,234	2026-03-31
Geode Capital Management, LLC	1,229	2026-03-31
Vanguard Capital Management LLC	158	2026-03-31
Tower Research Capital LLC (TRC)	72	2026-03-31
Vanguard Fiduciary Trust Co	68	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACXPAcurx Pharmaceuticals, Inc.	$1.27	+1.60%	-0.36	$5.46M	0.00%
ADILAdial Pharmaceuticals, Inc	$3.90	-1.76%	-0.26	$10.24M	0.00%
APREAprea Therapeutics, Inc.	$0.60	+8.28%	-0.64	$7.48M	0.00%
BCDABioCardia, Inc.	$1.04	-1.89%	-1.54	$15.48M	0.00%
BFRIBiofrontera Inc.	$0.97	+5.57%	-1.69	$12.42M	0.00%

About Profusa, Inc.

Profusa, Inc. is led by CEO Ben Chung-Bin Hwang, employs 2 people, headquartered in US, publicly traded since 2025.

Profusa, Inc. (PFSA) stock trades at $1.42 with a market capitalization of $1.57M. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of -0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.42 and $3000.00, and currently trades 100.0% below its 52-week high.

On profitability, Profusa, Inc. generates a return on equity (ROE) of 148.25% — well above the market average, a sign of a high-quality business, return on capital employed of 72.22%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides